Skip to main content

Table 1 Correlations between clusterin expression and clinicopathologic parameters and univariate analysis of survival in pancreatic adenocarcinoma

From: Clinical significance of clusterin expression in pancreatic adenocarcinoma

Parameter Number of cases (%) Clusterin expression Survival analysis
   Clusterin-positive cases (%) P value Median survival (months) P value
Overall 52 (100.0) 17 (32.7)   14.9  
Age    0.780   0.029
 ≥65 years 35 (67.3) 11 (31.4)   10.4  
  < 65 years 17 (32.7) 6 (35.3)   38.7  
Sex    0.747   0.792
 Male 37 (71.2) 13 (35.1)   15.0  
 Female 15 (28.8) 4 (26.7)   10.4  
Tumor size    0.241   0.075
 ≤2 cm 9 (17.3) 1 (11.1)   35.4  
  > 2 cm 43 (82.7) 16 (37.2)   14.7  
Location    0.413   0.648
 Head 44 (84.6) 13 (29.5)   15.0  
 Body/tail 8 (15.4) 4 (50.0)   9.9  
Pathologic grade    0.711   0.010
 Well/moderately differentiated 42 (80.8) 13 (31.0)   15.9  
 Poorly differentiated/anaplastic 10 (19.2) 4 (40.0)   3.1  
Perineural invasion    0.042   0.414
 No 8 (15.4) 0 (0.0)   18.5  
 Yes 44 (84.6) 17 (32.7)   11.5  
Lymphovascular invasion    0.330   0.055
 No 15 (28.8) 3 (20.0)   39.6  
 Yes 37 (71.2) 14 (37.8)   8.9  
Preoperative CEA (ng/ml)    0.048   0.787
 ≤5 32 (69.6) 8 (25.0)   15.0  
  > 5 14 (30.4) 8 (57.1)   14.7  
Preoperative CA19-9 (U/ml)    1.000   0.640
 ≤37 15 (33.3) 5 (33.3)   15.9  
  > 37 30 (66.7) 10 (33.3)   16.5  
Lymph node metastasis    0.006   0.002
 No 16 (31.4) 1 (6.3)   39.7  
 Yes 35 (68.6) 16 (45.7)   9.9  
Clusterin expression     0.312
 Negative 35 (67.3)   15.0  
 Positive 17 (32.7)   14.9  
  1. CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen.